Fig. 5From: A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trialNeither SB010 nor placebo led to statistically significant differences in lung function (a, b), CAT (c), or SGRQ (d) before/after 28 days treatment. Data are displayed as mean ± SEMBack to article page